Drug development consultancy Boyds has bolstered its clinical trials expertise with the appointment of Caroline Corbett as Director of Clinical Operations.
As Director of Clinical Operations at Boyds, Corbett will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth and development of the clinical operations team and service offering. Corbett will be based at the company’s Cambridge office and will focus on the delivery of study start-up activities, including site selection and reviewing clinical trial protocols.
Corbett brings over 15 years’ experience in Phase I to Phase IV clinical trials to Boyds, joining from IQVIA where she was the early clinical development portfolio oversight lead for two key partnerships. There, she helped oversee the delivery of more than 10 clinical studies and managed a 16-strong global team.
A specialist in the management of early phase studies, Corbett’s experience spans a variety of therapeutic areas including Covid-19, biosimilars, gene therapy, oncology, HIV, Parkinson’s, Migraine and Multiple Sclerosis, as well as healthy volunteer studies and first-in human (FIH) compounds.
Of her appointment, Corbett said: “I am excited to be returning to a specialist company where you can truly be at the forefront of science whilst closely collaborating with all team members involved in the delivery of a study. I hope to use my extensive experience in global programme and project management and first-hand monitoring to support both the clinical operations team and our clients as we aim to help bring more medicines to the market.”
Dr Karen O’Hanlon added: “We are delighted to be further expanding our clinical operations team. We have seen an increased demand for our study start up expertise, and Caroline’s appointment marks an exciting point in the team’s growth. Caroline is a highly experienced and capable clinical trial specialist with a strong track record of managing efficient, high-performing teams. The Clinical Operations team plays a key role in helping us support more clients translate their innovations into medicinal products for the benefit of patients around the world.”